Skip to main content

Table 1 The comparison between the infectious and non-infectious groups

From: Procalcitonin for the differential diagnosis of infectious and non-infectious systemic inflammatory response syndrome after cardiac surgery

 

Infectious SIRS (n = 47)

Non-infectious SIRS (n = 95)

p value

Age (year)

67.8 ± 15.7

67.2 ± 13.3

0.81

Gender, n (%)

  

0.77

 Male

32 (68.1)

67 (70.5)

 

 Female

15 (31.9)

28 (29.5)

 

Type of surgery, n (%)

   

 Valve surgery

16 (34.0)

36 (37.9)

0.65

 CABG

9 (19.1)

11 (11.6)

0.22

 Vessel replacement

13 (27.7)

21 (22.7)

0.47

 VAD

3 (6.4)

1 (1.1)

0.11

 Interventional therapy

1 (2.1)

14 (14.7)

0.02

 Complex surgery

5 (10.6)

12 (12.6)

0.73

BMI, kg/m2

21.8 (20.0,26.7)

22.7 (20.4,24.7)

0.64

Concomitant disease, n (%)

   

 Diabetes mellitus

18 (38.3)

25 (26.3)

0.14

 Hypertension

20 (42.6)

35 (36.8)

0.51

 CKD

19 (40.4)

21 (22.1)

0.02

CPB duration, min

197.2 ± 142.5

173.6 ± 123.5

0.31

Aortic cross clamping, min

99.0 ± 100.1

98.3 ± 84.7

0.96

Operation time, min

508.9 ± 192.4

466.3 ± 174.9

0.19

Blood loss, mL

3,512 ± 3,150

3,189 ± 2,706

0.53

APACHE II

19.0 (15.0,25.0)

11.0 (9.0,14.0)

0.001

SOFA

7.0 ± 2.6

5.1 ± 2.1

0.001

PCT, ng/mL

2.80 (1.24,10.20)

0.10 (0.06,0.21)

0.001

WBC, ×103/μL

15.5 (11.0,22.6)

9.3 (7.2,12.6)

0.001

CRP, mg/dL

15.8 (12.0,19.9)

5.8 (2.5,8.9)

0.001

ICU stay, day

23.0 (12.0,52.0)

5.0 (3.0,6.0)

0.001

Hospital stay, day

82.0 (37.0,149.0)

31.0 (23.0,45.0)

0.001

MV duration, h

264.0 (40.0,999.0)

17.0 (10.0,39.0)

0.001

CRRT, n (%)

26 (55.3)

5 (5.3)

0.001

PMX-DHP, n (%)

18 (38.3)

0

0.001

ECMO, n (%)

13 (27.7)

0

0.001

DIC, n (%)

23 (48.9)

0

0.001

30-Day mortality, n (%)

3 (6.38)

0

0.035

Hospital mortality, n (%)

22 (46.8)

0

0.001

  1. CABG coronary artery bypass graft, VAD ventricular assist device, BMI body mass index, CKD chronic kidney disease, CPB cardiopulmonary bypass, APACHE II acute physiology and chronic health evaluation II, SOFA sequential organ failure assessment, MV mechanical ventilation, CRRT continuous renal replacement therapy, PMX-DHP polymyxin B-immobilized fiber column direct hemoperfusion, ECMO extracorporeal membrane oxygenation, DIC disseminated intravascular coagulation.